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Signet-ring cell carcinoma (SRCC) can arise from virtually all organs. However, primary SRCC of the breast is very
rare. Until 2003, SRCC was placed under ‘mucin-producing carcinomas’ and separated from other carcinomas by the
World Health Organization (WHO). To date, only a few cases have been reported. A case of a 46-year-old woman
with primary SRCC of the breast is presented in this report. The patient underwent a right modified radical
mastectomy with axillary lymph node dissection. Characteristic features and differential diagnosis of this tumor are
discussed in the light of pertinent literature.
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Signet-ring cell carcinoma (SRCC) is a unique subtype
of mucin-producing adenocarcinoma that can arise
from the stomach, breast, colon, lung and prostate [1].
Primary SRCC of the breast is a very rare tumor, which
shows a significant number of tumor cells with intracel-
lular mucin accumulation [2,3]. In 1941, Saphir first
described this type of tumor as a variety of mucinous
carcinoma [4]. In 1976, Steinbrecher and Silverberg
reported five cases of rare carcinoma of the breast char-
acterized by the presence of numerous cells containing
intracellular mucin, without large amounts of extracel-
lular mucins seen in colloid carcinoma of the breast [5].
Hull et al. found 24 cases of SRCC, which represented
4.5% of 535 cases of surgically treated carcinomas of the
breast in their database; most cases were associated with
the ductal carcinoma and lobular carcinoma, and only
four cases were pure SRCC [2]. Until 2003, SRCC was
placed under ‘mucin-producing carcinomas’, and sepa-
rated from both infiltrating ductal and lobular carcin-
omas by the World Health Organization (WHO) [6].
Therefore, the frequency of this tumor was difficult to
evaluate because it was not a distinct type.* Correspondence: xiexm@sysucc.org.cn
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the breast. The characteristic clinical, morphological and
immunohistochemical features, and differential diagnosis
of this tumor are discussed.Case presentation
A 46-year-old woman presented to Sun Yat-sen University
Cancer Center, Guangzhou, China, with a lump in the
right breast discovered by self-examination one month
ago. The patient had no previous breast problems or
family history of breast cancer. Physical examination
revealed a firm, 10 mm × 5 mm mass in the upper outer
quadrant of the right breast, without evidence of axillary
or supraclavicular lymphadenopathy. There was no
tethering of the skin or peaud’orange. The contralateral
breast and axilla were normal, and the tested blood
parameters, chest X-ray, electrocardiography (ECG) and
heart functions were also normal.
Ultrasonography of the right breast showed a hypoechoic
area measuring approximately 10 mm × 7 mm in the
upper outer quadrant, demonstrating a circumscribed
complex echoic mass with posterior enhancement,
uneven density and abundant vessels. A preoperative
biopsy of the breast was planned under the guidance of
ultrasound. Mammography revealed heterogeneously
dense breasts, without any evidence of mass lesions,
architectural distortion or microcalcifications.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Histological findings of case study. The carcinoma showed invasive carcinoma, and partial presence of the in situ component of
carcinoma. (A) H&E stain, magnification × 40; (B) H&E stain, magnification × 200.
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tissue demonstrated that the tumor was SRCC, but it
was needed to distinguish whether it was derived from
metastasesto the breast from extramammary sites.
Gastrointestinal endoscopy was normal. Computer-
ized tomography (CT) scan of the neck, chest and
upper abdomen showed several enlarged lymph nodes
in the neck, but the thorax and abdomen were nor-
mal. Gastrointestinal ultrasonography also showed no
abnormality.
The patient underwent a right modified mastectomy
with axillary lymph node dissection, and received the
first course of chemotherapy 15 days later.Figure 2 Histological findings of case study. The carcinoma componen
and (C, D) signet-ring tumor cells.Histological findings
Gross pathologic examination of the right breast specimen
revealed a tumor, which measured 3.5 cm × 2.5 cm ×
1.5 cm in diameter. Microscopically, the right surgi-
cally resected mass showed invasive carcinoma and
partial presence of the in situ component of carcinoma
(Figure 1). The histological examination of the neo-
plastic cells showed that they were small and round,
scattered or funicular distribution, and with large
intracytoplasmic mucin compressing the nuclei toward
one pole of the cell (Figure 2). The majority (>50%) of
tumor cells showed features of signet-ring cells, with
high-grade nuclear atypia, moderate mitotic activityt comprised of intracytoplasmic mucin with (A, B) Alcianblue staining
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of the tumor was established as SRCC. There were 14
metastases found in 21 lymph nodes, with tumor emboli
in vessel.Immunohistochemical findings
Immunohistochemical examination of the neoplastic cells
demonstrated that part of the epithelial components
expressed cytokeratin. Tumor cells showed a negativeFigure 3 Immunohistochemical findings of the tumor. The signet-ring
(C) GCDFP-15, (D) mammaglobin, (E) Hep Par1, (F) TTF-1, (G) MUC2 and (H
receptor; GCDFP-15, gross cystic disease fluid protein-15; Hep Par1, hepatoc
SRCC, signet-ring cell carcinoma; TTF-1, thyroid transcription factor-1.reaction for estrogen receptor (ER), progesterone receptor
(PR), gross cystic disease fluid protein-15 (GCDFP-15),
mammaglobin, hepatocyte paraffin 1 (Hep Par1), thyroid
transcription factor-1 (TTF-1), mucin 2 glycoprotein
(MUC2) and cytokeratin 20 (CK20) (Figure 3); and a posi-
tive reaction for mucin 1 glycoprotein (MUC1), caudal
type homeobox 2 (CDX2), E-cadherin (E-ca) and
cytokeratin 7 (CK7), but weak expression focal for E-ca
(Figure 4). Table 1 presents a summary of antibodies used
in the assessment of the lesion.cell carcinoma (SRCC) component was negative for (A) ER, (B) PR,
) CK20; magnification × 200. CK20, cytokeratin 20; ER, estrogen
yte paraffin 1; MUC2, mucin 2 glycoprotein; PR, progesterone receptor;
Figure 4 Immunohistochemical findings of the tumor. The signet-ring cell carcinoma (SRCC) component was positive for (A) MUC1,
(B) CDX2, (C) E-ca and (D) CK7; magnification × 200; and furthermore, (E) E-ca and (F) CK7; magnification × 400. CDX2, caudal type homeobox 2;
CK7, cytokeratin 7; E-ca, E-cadherin; MUC1, mucin 1 glycoprotein; SRCC, signet-ring cell carcinoma.
Li et al. World Journal of Surgical Oncology 2013, 11:183 Page 4 of 6
http://www.wjso.com/content/11/1/183Discussion
Until now, only a few cases of SRCC of the breast have
been reported in the English literature, and the preva-
lence of signet-ring features has ranged from 2 to 4.5%
of total breast cancers [2,7,8].
SRCC of the breast can be divided into primary and
metastatic tumors. A variety of immunohistochemical
markers have been applied to distinguish SRCC from
different organs. SRCCs of the breast are generally
immunohistochemically positive for GCDFP-15, whereas
SRCCs of the gastrointestinal tract are negative [9]. Fur-
thermore, adenocarcinomas of the breast, stomach and
colon show different CK7 and CK20 expression patterns
[10-12]. ER is very often positive in primary SRCC of the
breast, but commonly negative in gastric and colonic
signet-ring cells. While primary SRCC of the breast is
typically positive for CK7 but negative for CK20, thegastrointestinal SRCCs are commonly positive for CK20
but usually negative for CK7. In combination with ER
staining, CK7 and CK20 expression patterns can be used
to distinguish gastrointestinal SRCC from SRCC of the
breast. Although ER is usually expressed in carcinoma of
the breast, approximately 20% of SRCCs of the breast
can be negative for ER [12]. In this case report, neoplastic
cells showed negative reaction for ER, PR, CK20 and
GCDFP-15, and positive reaction for CK7.
In recent years, new antibodies have been found use-
ful in the differential diagnosis. Adenocarcinomas of the
breast usually express MUC1 but not MUC2, whereas
gastrointestinal adenocarcinomas frequently express
MUC2 but less frequently express MUC1 [13,14]. The
combination of immunomarkers can substantially in-
crease the sensitivity and specificity for diagnosing
SRCCs of these organs. Chu et al. [1] found that the use
Table 1 Summary of antibodies used in the assessment of
the lesion
Antibody Company Clone Dilution
ER Ventana SP1 1:50
PR Ventana IE2 1:150
GCDFP-15 Dako 23A3 1:50
Mammaglobin Zeta Corporation 304-1A5 1:120
MUC1 Cell Marque Ma695 1:120
MUC2 Zeta Corporation Ccp58 1:120
CK7 Invitrogen OV-TL12/30 1:150
CK20 Epitomics EP23 1:150
CDX2 Epitomics EP25 1:200
E-ca Epitomics EP6 1:150
Hep Par 1 Zeta Corporation OCH1E5 1:150
TTF-1 LeicaMicrosystems SPT24 1:180
Cell Marque, Rocklin, CA, USA; Dako, Carpinteria, CA, USA; Epitomics,
Burlingame, CA, USA; Invitrogen, Carlsbad, CA, USA; Leica Microsystems,
Wetzlar, Germany; Ventana, Oro Valley, AZ, USA; Zeta Corporation, Sierra
Madre, CA, USA.CDX2, caudal type homeobox 2; CK7, cytokeratin 7; CK20,
cytokeratin 20; E-ca, E-cadherin; ER, estrogen receptor; GCDFP-15, gross cystic
disease fluid protein-15; Hep Par1, hepatocyte paraffin 1; MUC1, mucin 1
glycoprotein; MUC2, mucin 2 glycoprotein; PR, progesterone receptor; TTF-1,
thyroid transcription factor-1.
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gastrointestinal SRCC, if ER andMUC1 are used as
markers for SRCC of the breast, and MUC2 and CDX2
can be used as markers for gastric and colon SRCCs. To
distinguish SRCCs of gastric versus colonic origin, Hep
Par1 and CDX2 strongly favor a gastric primary site,
whereas Hep Par1 negativity and MUC2 positivity
strongly favor a colonic primary site. E-ca is less useful
and lacks sensitivity. In this report, tumor cells showed
positive reaction for E-ca, CDX2 and MUC1, and nega-
tive reaction for MUC2, Hep Par1 and TTF-1. The car-
cinoma of this report comprised of intracytoplasmic
mucin and signet-ring tumor cells, with a lack of typical
features on immunohistochemical examination, but no
sign of tumor in any other organs by radiology imaging.
The immunophenotype of this case is highly unusual
and the presence of a coexisting in situ ductal compo-
nent strongly favors a primary breast site.
Regardless of the tissue origin, SRCCs frequently
metastasize to regional lymph nodes, peritoneal surfaces,
ovaries and lungs [1]. In pure SRCC of the breast, the
lesion is more aggressive than mucinous carcinoma,
invasive ductal carcinoma of no special type and classic
invasive lobular carcinoma [3]. In this case report, there
were 14 metastases found in 21 lymph nodes, with
tumor emboli in vessel. The presence of 10% or more of
signet-ring cells has been reported to be a poor individual
prognostic factor in stage I infiltrating lobular carcinomas
[15]. Consequently, it is important to distinguish primary
and metastatic tumors because of their significantdifference in therapy and prognosis. Immunohisto-
chemistry may be particularly helpful in differentiating
the tumors [2,3,16-19].
Treatment and prognosis of SRCC of the breast has
been reported less frequently in the literature on account
of its rarity. However, Eltorky et al. [20] reported that
both the pathologist and the clinician should be aware
of the prognostic influence of hormone receptor studies
in the management of SRCC of the breast.
Conclusions
Primary SRCC of the breast is a very rare malignant tumor
and must be distinguished from metastases of SRCCs to
the breast. The prognosis of this tumor is usually poor but
early detection may provide a good result. It is important
to differentiate this type of tumor according to the patho-
logical and clinical characteristics.
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